| Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer (NCT04781413) | Ruijin Hospital | 2021-03-01 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery (NCT02511821) | City of Hope Medical Center | 2015-07-22 |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer (NCT02344810) | Eastern Cooperative Oncology Group | 2015-03-06 |
| Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (NCT02366819) | University of Chicago | 2014-12-11 |
| 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer (NCT01939275) | City of Hope Medical Center | 2014-11-19 |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers (NCT01846520) | City of Hope Medical Center | 2013-10-01 |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (NCT01612546) | City of Hope Medical Center | 2012-11-01 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (NCT01212822) | Fox Chase Cancer Center | 2011-04-27 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer (NCT01178944) | Roswell Park Cancer Institute | 2010-09-01 |
| Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer (NCT00982592) | National Cancer Institute (NCI) | 2009-09-01 |
| Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery (NCT00991952) | National Cancer Institute (NCI) | 2009-09-01 |
| Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT00084604) | National Cancer Institute (NCI) | 2004-04-01 |
| Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma (NCT00084617) | National Cancer Institute (NCI) | 2004-03-01 |